Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.69 |
| ▸ | CCR1 | P32246 | 4/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 5/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | STAT6 | P42226 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4972415 | 1.00 | TRPV4 (0.69) | TRPV4CCR1TAS1R3TAS1R1CTSK | |
| SCHEMBL5007974 | 1.00 | TRPV4 (0.69) | TRPV4CCR1TAS1R3TAS1R1CTSK | |
| SCHEMBL14495379 | 0.92 | TRPV4 (0.72) | TRPV4CCR1TAS1R3TAS1R1CTSK | |
| SCHEMBL4973245 | 0.90 | TRPV4 (0.67) | TRPV4CCR1TAS1R3TAS1R1CTSK | |
| SCHEMBL3065328 | 0.83 | TRPV4 (0.65) | TRPV4CCR1TAS1R3TAS1R1CTSK | |
| SCHEMBL5004275 | 0.82 | TRPV4 (0.87) | TRPV4CCR1TAS1R3TAS1R1CTSK | |
| SCHEMBL4976960 | 0.82 | TRPV4 (0.72) | TRPV4CCR1TAS1R3TAS1R1CTSK | |
| SCHEMBL4976956 | 0.82 | TRPV4 (0.72) | TRPV4CCR1TAS1R3TAS1R1CTSK | |
| SCHEMBL5007269 | 0.82 | TRPV4 (0.46) | TRPV4CCR1 | |
| SCHEMBL4972091 | 0.82 | TRPV4 (0.74) | TRPV4CCR1TAS1R3TAS1R1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318945-A1 | Novel Compounds | CASILLAS LINDA N | 2008-12-25 | — | — | US | claimed |
| EP-1968590-A2 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-09-17 | — | — | EP | claimed |
| WO-2007070865-A2 | PIPERAZINE COMPOUNDS AS AGONISTS OF TRPV4 CHANNEL RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-21 | — | — | WO | claimed |
| US-20080318945-A1 | Novel Compounds | CASILLAS LINDA N | 2008-12-25 | — | — | US | disclosed |
| US-20080318945-A1 | Novel Compounds | CASILLAS LINDA N | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318945-A1 | Novel Compounds | TRPV4, TRPV1, TRPV3 | TRPV4 1/4885CCR1 919/4885TAS1R3 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.